Tenofovir alafenamide and rifabutin coadministration does not lead to loss of HIV-1 suppression: a retrospective observational study

Tenofovir alafenamide (TAF), a prodrug of tenofovir, is a well-tolerated and efficacious nucleotide reverse transcriptase inhibitor approved for the treatment of HIV (Eron et al., 2018, Sax et al., 2014, Wang et al., 2016). Due to lower plasma but higher intracellular concentrations of tenofovir diphosphate (TFV-DP), the active drug metabolite, TAF is associated with reduced renal and bone toxicities compared to tenofovir disoproxil fumarate (TDF) (Gupta et al., 2019, Wang et al., 2016). Because of its favourable safety profile, TAF is a component of several recommended initial antiretroviral therapy (ART) regimens (Panel on Antiretroviral Guidelines for Adults and Adolescents).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Short Communication Source Type: research